{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:30:24Z","timestamp":1790767824022,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["20K17418"],"award-info":[{"award-number":["20K17418"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-021-04944-x","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T07:03:02Z","timestamp":1625814182000},"page":"1983-1991","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neutrophil count reduction 1\u00a0month after initiating tocilizumab can predict clinical remission within 1\u00a0year in rheumatoid arthritis patients"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-034X","authenticated-orcid":false,"given":"Tomoya","family":"Nakajima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1089-5296","authenticated-orcid":false,"given":"Ryu","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9241-060X","authenticated-orcid":false,"given":"Motomu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7896-3937","authenticated-orcid":false,"given":"Koichi","family":"Murata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5981-4648","authenticated-orcid":false,"given":"Kosaku","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2933","authenticated-orcid":false,"given":"Masao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1827-382X","authenticated-orcid":false,"given":"Hiromu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0810-4221","authenticated-orcid":false,"given":"Wataru","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-8648","authenticated-orcid":false,"given":"Koji","family":"Kitagori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Akizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6247-0647","authenticated-orcid":false,"given":"Ran","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-4900","authenticated-orcid":false,"given":"Hajime","family":"Yoshifuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-9159","authenticated-orcid":false,"given":"Koichiro","family":"Ohmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-1255","authenticated-orcid":false,"given":"Shuichi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4672-638X","authenticated-orcid":false,"given":"Akio","family":"Morinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"13","key":"4944_CR1","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2018.13103","volume":"320","author":"D Aletaha","year":"2018","unstructured":"Aletaha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360\u20131372. https:\/\/doi.org\/10.1001\/jama.2018.13103","journal-title":"JAMA"},{"issue":"1","key":"4944_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"JM Dayer","year":"2010","unstructured":"Dayer JM, Choy E (2010) Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology 49(1):15\u201324. https:\/\/doi.org\/10.1093\/rheumatology\/kep329","journal-title":"Rheumatology"},{"issue":"6","key":"4944_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79(6):685\u2013699. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4944_CR4","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen JS, Aletaha D, Bijlsma JWJ et al (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 69(4):631\u2013637. https:\/\/doi.org\/10.1136\/ard.2009.123919","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4944_CR5","doi-asserted-by":"publisher","first-page":"3603","DOI":"10.1093\/rheumatology\/keaa529","volume":"59","author":"B Nouri","year":"2020","unstructured":"Nouri B, Nair N, Barton A (2020) Predicting treatment response to IL6R blockers in rheumatoid arthritis. Rheumatology 59(12):3603\u20133610. https:\/\/doi.org\/10.1093\/rheumatology\/keaa529","journal-title":"Rheumatology"},{"issue":"4","key":"4944_CR6","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1093\/rheumatology\/kew370","volume":"56","author":"RJ Moots","year":"2017","unstructured":"Moots RJ, Sebba A, Rigby W et al (2017) Effect of tocilizumab on neutrophils in adult patients with rheumatoid arthritis: pooled analysis of data from phase 3 and 4 clinical trials. Rheumatology 56(4):541\u2013549. https:\/\/doi.org\/10.1093\/rheumatology\/kew370","journal-title":"Rheumatology"},{"issue":"3","key":"4944_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315\u2013324. https:\/\/doi.org\/10.1002\/art.1780310302","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4944_CR8","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69(9):1580\u20131588. https:\/\/doi.org\/10.1136\/ard.2010.138461","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"4944_CR9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1111\/1756-185x.13428","volume":"22","author":"K Murata","year":"2019","unstructured":"Murata K, Ito H, Hashimoto M et al (2019) Elderly onset of early rheumatoid arthritis is a risk factor for bone erosions, refractory to treatment: KURAMA cohort. Int J Rheum Dis 22(6):1084\u20131093. https:\/\/doi.org\/10.1111\/1756-185x.13428","journal-title":"Int J Rheum Dis"},{"issue":"5 Suppl 39","key":"4944_CR10","first-page":"S100","volume":"23","author":"D Aletaha","year":"2005","unstructured":"Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23(5 Suppl 39):S100-108","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"4944_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/art.27740","volume":"63","author":"JS Smolen","year":"2011","unstructured":"Smolen JS, Aletaha D (2011) Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. Arthritis Rheum 63(1):43\u201352. https:\/\/doi.org\/10.1002\/art.27740","journal-title":"Arthritis Rheum"},{"issue":"3","key":"4944_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48(3):452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"4944_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/rheumatology\/ket301","volume":"53","author":"YM Pers","year":"2014","unstructured":"Pers YM, Fortunet C, Constant E et al (2014) Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology 53(1):76\u201384. https:\/\/doi.org\/10.1093\/rheumatology\/ket301","journal-title":"Rheumatology"},{"issue":"4","key":"4944_CR14","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.semarthrit.2015.07.001","volume":"45","author":"J Narv\u00e1ez","year":"2016","unstructured":"Narv\u00e1ez J, Magallares B, D\u00edaz Torn\u00e9 C et al (2016) Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Semin Arthritis Rheum 45(4):386\u2013390. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.07.001","journal-title":"Semin Arthritis Rheum"},{"issue":"21","key":"4944_CR15","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1161\/01.cir.98.21.2307","volume":"98","author":"M Nakagawa","year":"1998","unstructured":"Nakagawa M, Terashima T, D\u2019yachkova Y, Bondy GP, Hogg JC, Van Eeden SF (1998) Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 98(21):2307\u20132313. https:\/\/doi.org\/10.1161\/01.cir.98.21.2307","journal-title":"Circulation"},{"issue":"7","key":"4944_CR16","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/rheumatology\/keu455","volume":"54","author":"H Forsblad-d\u2019Elia","year":"2015","unstructured":"Forsblad-d\u2019Elia H, Bengtsson K, Kristensen LE, Jacobsson LTH (2015) Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology 54(7):1186\u20131193. https:\/\/doi.org\/10.1093\/rheumatology\/keu455","journal-title":"Rheumatology"},{"issue":"5","key":"4944_CR17","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s10165-012-0782-y","volume":"23","author":"T Kojima","year":"2013","unstructured":"Kojima T, Yabe Y, Kaneko A et al (2013) Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod Rheumatol 23(5):977\u2013985. https:\/\/doi.org\/10.1007\/s10165-012-0782-y","journal-title":"Mod Rheumatol"},{"issue":"9","key":"4944_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/art.41299","volume":"72","author":"A Boyapati","year":"2020","unstructured":"Boyapati A, Schwartzman S, Msihid J et al (2020) Association of high serum interleukin-6 levels with severe progression of rheumatoid arthritis and increased treatment response differentiating sarilumab from adalimumab or methotrexate in a post hoc analysis. Arthritis Rheum 72(9):1456\u20131466. https:\/\/doi.org\/10.1002\/art.41299","journal-title":"Arthritis Rheum"},{"issue":"2","key":"4944_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/rheumatology\/keaa259","volume":"60","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Aletaha D, Devenport J et al (2020) Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. Rheumatology 60(2):682\u2013691. https:\/\/doi.org\/10.1093\/rheumatology\/keaa259","journal-title":"Rheumatology"},{"issue":"3","key":"4944_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00296-015-3379-x","volume":"36","author":"T Okano","year":"2016","unstructured":"Okano T, Inui K, Tada M et al (2016) Levels of interleukin-1 beta can predict response to tocilizumab therapy in rheumatoid arthritis: the PETITE (predictors of effectiveness of tocilizumab therapy) study. Rheumatol Int 36(3):349\u2013357. https:\/\/doi.org\/10.1007\/s00296-015-3379-x","journal-title":"Rheumatol Int"},{"issue":"1","key":"4944_CR21","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","volume":"17","author":"S Hirata","year":"2015","unstructured":"Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y (2015) Serum 14\u20133-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther 17(1):280. https:\/\/doi.org\/10.1186\/s13075-015-0799-7","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"4944_CR22","doi-asserted-by":"publisher","first-page":"R90","DOI":"10.1186\/ar4555","volume":"16","author":"G Dennis","year":"2014","unstructured":"Dennis G, Holweg CTJ, Kummerfeld SK et al (2014) Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther 16(2):R90. https:\/\/doi.org\/10.1186\/ar4555","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"4944_CR23","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/annrheumdis-2013-204137","volume":"73","author":"N Nishina","year":"2014","unstructured":"Nishina N, Kikuchi J, Hashizume M, Yoshimoto K, Kameda H, Takeuchi T (2014) Baseline levels of soluble interleukin-6 receptor predict clinical remission in patients with rheumatoid arthritis treated with tocilizumab: implications for molecular targeted therapy. Ann Rheum Dis 73(5):945\u2013947. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204137","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"4944_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/rheumatology\/keu363","volume":"54","author":"CI Da\u00efen","year":"2015","unstructured":"Da\u00efen CI, Gaihac S, Audo R et al (2015) High levels of natural killer cells are associated with response to tocilizumab in patients with severe rheumatoid arthritis. Rheumatology 54(4):601\u2013608. https:\/\/doi.org\/10.1093\/rheumatology\/keu363","journal-title":"Rheumatology"},{"issue":"8","key":"4944_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/fpc.0000000000000071","volume":"24","author":"C Enevold","year":"2014","unstructured":"Enevold C, Baslund B, Linde L et al (2014) Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics 24(8):401\u2013405. https:\/\/doi.org\/10.1097\/fpc.0000000000000071","journal-title":"Pharmacogenet Genomics"},{"key":"4944_CR26","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.phrs.2016.06.016","volume":"111","author":"M Maldonado-Montoro","year":"2016","unstructured":"Maldonado-Montoro M, Ca\u00f1adas-Garre M, Gonz\u00e1lez-Utrilla A, Plaza-Plaza JC, Calleja-Hern\u00e1ndez M\u0178 (2016) Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res 111:264\u2013271. https:\/\/doi.org\/10.1016\/j.phrs.2016.06.016","journal-title":"Pharmacol Res"},{"key":"4944_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1136\/annrheumdis-2014-eular.2293","volume":"73","author":"Y Sanayama","year":"2014","unstructured":"Sanayama Y, Ikeda K, Saito Y et al (2014) Prediction of therapeutic responses to TOCILIZUMAB in patients with rheumatoid arthritis using biomarkers identified by genome-wide DNA microarray analysis in peripheral blood mononuclear cells. Ann Rheum Dis 73:383. https:\/\/doi.org\/10.1136\/annrheumdis-2014-eular.2293","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"4944_CR28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/cncr.11882","volume":"100","author":"J Crawford","year":"2004","unstructured":"Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: Risks, consequences, and new directions for its management. Cancer 100(2):228\u2013237. https:\/\/doi.org\/10.1002\/cncr.11882","journal-title":"Cancer"},{"issue":"10","key":"4944_CR29","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrrheum.2014.80","volume":"10","author":"HL Wright","year":"2014","unstructured":"Wright HL, Moots RJ, Edwards SW (2014) The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol 10(10):593\u2013601. https:\/\/doi.org\/10.1038\/nrrheum.2014.80","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"4944_CR30","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2567.2006.02424.x","volume":"119","author":"D Tanaka","year":"2006","unstructured":"Tanaka D, Kagari T, Doi H, Shimazato T (2006) Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology 119(2):195\u2013202. https:\/\/doi.org\/10.1111\/j.1365-2567.2006.02424.x","journal-title":"Immunology"},{"issue":"8","key":"4944_CR31","first-page":"1510","volume":"24","author":"A Desgeorges","year":"1997","unstructured":"Desgeorges A, Gabay C, Silacci P et al (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol 24(8):1510\u20131516","journal-title":"J Rheumatol"},{"issue":"6","key":"4944_CR32","doi-asserted-by":"publisher","first-page":"H2954","DOI":"10.1152\/ajpheart.2000.279.6.H2954","volume":"279","author":"T Suwa","year":"2000","unstructured":"Suwa T, Hogg JC, English D, Van Eeden SF (2000) Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 279(6):H2954\u2013H2960. https:\/\/doi.org\/10.1152\/ajpheart.2000.279.6.H2954","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"4944_CR33","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","volume":"53","author":"HL Wright","year":"2014","unstructured":"Wright HL, Cross AL, Edwards SW, Moots RJ (2014) Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology 53(7):1321\u20131331. https:\/\/doi.org\/10.1093\/rheumatology\/keu035","journal-title":"Rheumatology"},{"issue":"1","key":"4944_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cyto.2011.01.007","volume":"54","author":"M Hashizume","year":"2011","unstructured":"Hashizume M, Higuchi Y, Uchiyama Y, Mihara M (2011) IL-6 plays an essential role in neutrophilia under inflammation. Cytokine 54(1):92\u201399. https:\/\/doi.org\/10.1016\/j.cyto.2011.01.007","journal-title":"Cytokine"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04944-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-021-04944-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-021-04944-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T11:09:57Z","timestamp":1664190597000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-021-04944-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":34,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["4944"],"URL":"https:\/\/doi.org\/10.1007\/s00296-021-04944-x","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Department of Advanced Medicine for Rheumatic Diseases is supported by Nagahama City, Shiga, Japan, Toyooka City, Hyogo, Japan and five pharmaceutical companies (Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, UCB Japan Co. Ltd, AYUMI Pharmaceutical Co., and Asahi Kasei Pharma Corp.). The KURAMA cohort is also supported by grant from Daiichi Sankyo Co. Ltd. The above-mentioned pharmaceutical companies were not involved in the study design, data collection and analysis, manuscript writing, and manuscript submission. RW received speaker fees from Mitsubishi Tanabe Pharma, Pfizer, Sanofi, AbbVie, Asahi Kasei, Eisai, Eli Lilly, Bristol-Myers Squibb, and Janssen. MH received a research grant and\/or speaker fees from Bristol-Myers, Eisai, Ely Lilly, Mitsubishi Tanabe Pharma, Novartis Pharma. KMurat received a speaking fee from Eisai Co., Ltd. and Astellas Pharma Inc. KMurak has received speaking fees from Eisai Co. Ltd, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Bristol-Myers Squibb, Mitsubishi Tanabe Pharma Corporation, UCB Japan Co. Ltd, Daiichi Sankyo Co. Ltd. and Astellas Pharma Inc.. MT received research grants and\/or speaker fees from AbbVie GK, Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Eisai Co., Ltd., Eli Lilly Japan K.K., Pfizer Inc., UCB Japan Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, Novartis Pharma K.K., Daiichi Sankyo Co. Ltd., Celgene Corp., Takeda Pharmaceutical Company Ltd., and Taisho Pharma Co., Ltd.. HI has received a research grant from Bristol-Myers Squibb, Asahi Kasei Pharma Corporation, Eisai, Mochida and Taisho. KK received research grants from GSK. RN has received research grants from Takeda and Medical & Biological Laboratories Co., Ltd. and speaking fees from Bristol-Myers Squibb, Astellas Pharma, Boehringer Ingelheim, Actelion Pharmaceuticals and Mitsubishi Tanabe Pharma, outside the submitted work. HY received lecture fees from Chugai and has been on the advisory board for a clinical trial conducted by Janssen. KO received research grants and\/or speaker fees from AbbVie, Actelion Pharmaceuticals, Asahi Kasei Pharma, Astellas Pharma, Ayumi Pharmaceutical, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly, GSK, JB, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma, Nippon Kayaku, Nippon Shinyaku, Mitsubishi Tanabe Pharma, Novartis Pharma, Sanofi, Takeda Pharmaceutical. SM has received a research grant and\/or speaker fee from Kyocera Medical Co., Mitsubishi Tanabe Pharma Co., Chugai Pharmaceutical Co. Ltd, Eisai Co., Ltd., Pfizer, Eli Lilly, Taisho Pharma Co., Ltd., and Ono Pharmaceutical Co.. AM has received research grants from AbbVie, Asahi Kasei Pharma, Chugai Pharmaceutical, Ono Pharmaceutical and speaking fees from Eli Lilly, AbbVie, Ono Pharmaceutical, Pfizer, Astellas Pharmaceutical, Chugai Pharmaceutical. All other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by the Ethics Committee of Kyoto University Graduate School and Faculty of Medicine (No. R0357).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to participate in the KURAMA cohort was obtained from all patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Written informed consent to publish the study results was obtained from all patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}